The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease
Open accessAbstract
Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181, p-tau217 and p-tau231 measured using 10 assays to detect abnormal brain amyloid-β (Aβ) status and predict future progression to Alzheimer's dementia. The study included 135 patients with baseline diagnosis of mild cognitive impairment (mean age 72.4 years; 60.7% women) who were followed for an average of 4.9 years. Seventy-one participants had abnormal Aβ-status (i.e. abnormal CSF Aβ42/40) at baseline; and 45 of these Aβ-positive participants progressed to Alzheimer's dementia during follow-up. P-tau concentrations were determined in baseline plasma and CSF. P-tau217 and p-tau181 were both measured using immunoassays developed by Lilly Research Laboratories (Lilly) and mass spectrometry assays developed at Washington University (WashU). P-tau217 was also analysed using Simoa immunoassay developed by Janssen Research and Development (Janss). P-tau181 was measured using Simoa immunoassay from ADxNeurosciences (ADx), Lumipulse immunoassay from Fujirebio (Fuji) and Splex immunoassay from Mesoscale Discovery (Splex). Both p-tau181 and p-tau231 were quantified using Simoa immunoassay developed at the University of Gothenburg (UGOT). We found that the mass spectrometry-based p-tau217 (p-tau217WashU) exhibited significantly better performance than all other plasma p-tau biomarkers when detecting abnormal Aβ status [area under curve (AUC) = 0.947; Pdiff < 0.015] or progression to Alzheimer's dementia (AUC = 0.932; Pdiff < 0.027). Among immunoassays, p-tau217Lilly had the highest AUCs (0.886–0.889), which was not significantly different from the AUCs of p-tau217Janss, p-tau181ADx and p-tau181WashU (AUCrange 0.835–0.872; Pdiff > 0.09), but higher compared with AUC of p-tau231UGOT, p-tau181Lilly, p-tau181UGOT, p-tau181Fuji and p-tau181Splex (AUCrange 0.642–0.813; Pdiff ≤ 0.029). Correlations between plasma and CSF values were strongest for p-tau217WashU (R = 0.891) followed by p-tau217Lilly (R = 0.755; Pdiff = 0.003 versus p-tau217WashU) and weak to moderate for the rest of the p-tau biomarkers (Rrange 0.320–0.669). In conclusion, our findings suggest that among all tested plasma p-tau assays, mass spectrometry-based measures of p-tau217 perform best when identifying mild cognitive impairment patients with abnormal brain Aβ or those who will subsequently progress to Alzheimer's dementia. Several other assays (p-tau217Lilly, p-tau217Janss, p-tau181ADx and p-tau181WashU) showed relatively high and consistent accuracy across both outcomes. The results further indicate that the highest performing assays have performance metrics that rival the gold standards of Aβ-PET and CSF. If further validated, our findings will have significant impacts in diagnosis, screening and treatment for Alzheimer's dementia in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among different p-tau variants, tau phosphorylated at threonine 217 (p-tau217) has demonstrated the highest accuracy in detecting AD pathology and predicting future cognitive decline23,27,29–31.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Potentially because %p-tau217 is less affected by confounding factors, this blood test has the highest performance yet demonstrated in identifying individuals with AD pathology29.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among proposed blood tau biomarkers,18,19,20,21 phosphorylated tau at threonine 217 (p-tau217) has consistently shown high performance in differentiating AD from other neurodegenerative disorders10,22 and in detecting AD pathology in patients with mild cognitive impairment (MCI).22”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Several recent studies have reported that plasma biomarkers have excellent diagnostic accuracy for AD, with sensitivity or specificity often exceeding 90% (refs. 4–10).”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“However, it is important to emphasize that head-to-head studies indicate that different assays for p-tau181 vary substantially in their diagnostic performance9,10 and may not all perform inferiorly to GFAP in all contexts34,43.”
From Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability (2024) · cites this paper as [10]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
pROC: an open-source package for R and S+ to analyze and compare ROC curves
Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., & Müller, M. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-77 · Cited by 13,697
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationPalmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603 · cited 3×
“7 The higher performance of p-tau217 over p-tau181 has been shown for immunoassays-based p-tau measures 10,12,13 as well as for CSF p-tau217 and p-tau181 34,35 and could be due to the specificity of p-tau217 for Alzheimer’s disease (this biomarker is found at considerably lower levels in people…”
Self-citationKarikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
Self-citation
Research works printed but not linked: 1
- Team, 2014, R: A Language and Environment for Statistical Computing
Cited by
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationDiagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“https://doi.org/10.1038/s41591-024-02869-z Potentially because %p-tau217 is less affected by confounding factors, this blood test has the highest performance yet demonstrated in identifying individuals with AD pathology 29 .”
BackgroundInfluentialSelf-citationBlood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Schindler, S. E., Smith, R., Ossenkoppele, R., Calling, S., West, T., Monane, M., Verghese, P. B., et al. (2024) · JAMA · doi:10.1001/jama.2024.13855 · Cited by 416
Self-citation
Metadata
- Authors
- Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., Pontecorvo, M. J., Zetterberg, H., Kolb, H., Vandijck, M., Blennow, K., Bateman, R. J., & Hansson, O.
- Affiliations
- Lund University (SE)
- King's College London (GB)
- Washington University in St. Louis (US)
- ADx NeuroSciences (BE)
- Neuroscience Biomarkers, Janssen Research & Development , La Jolla, CA , USA
- Eli Lilly (United States) (US)
- Sahlgrenska University Hospital (SE)
- Janssen Research & Development (United States) (US)
- Fujirebio (Belgium) (BE)
- Corresponding author
- Hansson, Oskar
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-09-10
- Volume
- 146
- Issue
- 4
- Pages
- 1592-1601
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC10115176
- OpenAlex
- W4295107480
- Cited by
- 522
- References
- 35
- Citations by year
- 2026: 118 · 2025: 173 · 2024: 155 · 2023: 70 · 2022: 5
- FWCI
- 65.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Brain (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Swedish Research Council
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
- Skåne University Hospital
- Alzheimer Drug Discovery Foundation
- Joint Programme – Neurodegenerative Disease Research
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- p-tau181, p-tau217, p-tau231, Alzheimer's disease, prodromal Alzheimer's disease, mild cognitive impairment, blood biomarkers, immunoassay comparison, mass spectrometry assay
- MeSH terms
- Aged, Alzheimer Disease, Brain, Female, Humans, Male, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. https://app.cochat.ai/papers/10.1093/brain/awac333
- The paper
- Janelidze, S., Bali, D., Ashton, N. J., Barthélemy, N. R., Vanbrabant, J., Stoops, E., Vanmechelen, E., He, Y., Dolado, A. O., Triana-Baltzer, G., Pontecorvo, M. J., Zetterberg, H., Kolb, H., Vandijck, M., Blennow, K., Bateman, R. J., & Hansson, O. (2023). Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain. https://doi.org/10.1093/brain/awac333
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.